Sunday, October 4, 2026
28.3 C
Bengaluru

Creador Bets Big on Indian Pharma with 7% La Renon Stake

In a significant development for the Indian pharmaceutical industry, Kuala Lumpur-based private equity firm Creador has acquired a 7% stake in Ahmedabad-headquartered La Renon Healthcare for ₹800 crore. This investment values La Renon at nearly ₹11,000 crore, marking a major milestone in the company’s rapid growth journey and reflecting robust investor confidence in India’s pharmaceutical sector.

Background of the Deal

The new transaction builds on La Renon’s earlier funding successes and sharp valuation rise. Post-deal, the promoter family led by Pankaj Singh retains a controlling 66% stake, while private equity investors including ChrysCapital, Peak XV Partners, A91 Partners, and Avendus collectively hold 34%. Specifically, the promoter family is selling about 5% of equity, with Peak XV offloading around 2% to accommodate the new investment.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

With over three decades of experience in the pharmaceutical...

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

India’s anaemia challenge is not simply about access to...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

Topics

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

A Tale of Two Cities: Peptides and Prescriptions

What our health choices reveal about education, access and...

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

MedicinMan Intelligent Insights When Air India CEO Tewolde Gebremariam...
spot_img

Related Articles

spot_imgspot_img